Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia

Blood
Mariano MonzoCETLAM

Abstract

Current prognostic factors for acute myeloblastic leukemia (AML) are not sufficient to accurately predict the group of patients in the intermediate-risk category who will successfully respond to treatment. Distinct patterns of inherited functional genomic polymorphisms might explain part of these heterogeneous prognoses. We used the allelic discrimination method to identify polymorphisms in GSTT1, SULT1C2, CDA, SXR (drug metabolic pathways), XPD, XPA, XPG, ERCC1, TOP2A (DNA repair), VEGF (angiogenesis), and MDR1 (multidrug resistance) genes in 110 adult patients with intermediate-risk AML, enrolled in the CETLAM-99 prospective trial. A multivariate prognostic model adjusted for age, white blood cell (WBC) count, French-American-British group, cytogenetics, MLL rearrangement, internal tandem duplication of FLT3 (FLT3-ITD), induction courses to achieve complete remission, and germline polymorphisms, was used to detect independent risk factors associated with clinical outcome. This analysis showed an increased risk of refractoriness to chemotherapy in the group of patients with XPA variant alleles (RR = 14; P = .02). In the same model, increased relapse risk was associated with SULT1C2 heterozygosity (RR = 4.1; P = .004), FLT3-ITD...Continue Reading

References

Sep 1, 1977·Clinical Pharmacology and Therapeutics·D E Drayer, M M Reidenberg
Mar 1, 1993·Environmental Health Perspectives·E KriekA P Dijkmans
Jan 1, 1996·Annual Review of Biochemistry·A Sancar
Apr 24, 1999·Biochimie·C Petit, A Sancar
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Jan 5, 2000·The Journal of Investigative Dermatology·T M RüngerD Hellfritsch
Nov 4, 2000·Journal of the National Cancer Institute·Q WeiM R Spitz
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M DaviesJ P Perentesis
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W E EvansM V Relling
May 18, 2001·Best Practice & Research. Clinical Haematology·P B LangmuirB J Lange
Aug 15, 2001·Clinical Pharmacology and Therapeutics·R B KimG R Wilkinson
Nov 10, 2001·Annual Review of Genomics and Human Genetics·W E Evans, J A Johnson
Mar 20, 2002·Nature Reviews. Cancer·E C Friedberg
May 23, 2002·International Journal of Colorectal Disease·David J ParkHeinz-Josef Lenz
Jul 18, 2002·Journal of the National Cancer Institute·Carol H BoskenMargaret R Spitz
Nov 26, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Rafael RosellNoemi Reguart
Feb 7, 2003·The New England Journal of Medicine·Richard Weinshilboum
May 17, 2003·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Jan Stoehlmacher, Heinz-Josef Lenz
Aug 7, 2003·Current Opinion in Pharmacology·David J ParkHeinz-Josef Lenz
Oct 18, 2003·Laboratory Investigation; a Journal of Technical Methods and Pathology·Friedemann HoneckerLeendert H J Looijenga
Nov 25, 2003·Hematology·Bob LöwenbergMartin S Tallman
Apr 16, 2004·The New England Journal of Medicine·Lars BullingerJonathan R Pollack
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Apr 16, 2004·The New England Journal of Medicine·David Grimwade, Torsten Haferlach
May 15, 2004·British Journal of Haematology·Richard Aplenc, Beverly Lange
Jun 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sarada GurubhagavatulaDavid C Christiani
Jun 11, 2004·Annual Review of Biochemistry·Aziz SancarStuart Linn
Jul 17, 2004·Neoplasia : an International Journal for Oncology Research·Paul W SchenkKees Nooter
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Jan 26, 2005·British Journal of Haematology·Markus SchaichUNKNOWN SHG AML96 Study Group
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephanie Q Hutsell, Aziz Sancar
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jian GuXifeng Wu

❮ Previous
Next ❯

Citations

Oct 23, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Mariano MonzóRosa Artells
Sep 13, 2012·International Journal of Hematology·Peipei XuZuhong Lu
Jan 16, 2009·Journal of Gastroenterology and Hepatology·Yong Seok KimKi Baik Hahm
Feb 5, 2008·Pharmacogenomics·Marc Ansari, Maja Krajinovic
Jul 27, 2012·Cellular and Molecular Life Sciences : CMLS·Kim R KampenEveline S J M de Bont
Mar 29, 2011·Leukemia & Lymphoma·Panagiota EconomopoulouTheofanis Economopoulos
Sep 10, 2013·Drug Metabolism Reviews·Jaclyn Daniels, Susan Kadlubar
Sep 14, 2013·Drug Metabolism Reviews·Melissa Runge-Morris, Thomas A Kocarek
Jun 29, 2013·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Chrysoula DoxaniElias Zintzaras
Jan 19, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Claudia BănescuErzsebeth Lazar
Feb 2, 2010·Hematology/oncology Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Sep 12, 2015·Journal of Human Genetics·Lyoung Hyo KimSung-Soo Yoon
Feb 5, 2008·Pediatric Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Sep 6, 2007·Cancer·Farhad RavandiHagop M Kantarjian
Aug 26, 2011·International Journal of Cancer. Journal International Du Cancer·Dapeng DingWenling Zheng
Mar 5, 2011·Molecular Carcinogenesis·Claudia M MonroyRanda El-Zein
Jul 7, 2016·Pharmacogenomics·Juan Eduardo Megías-VericatSalvador F Aliño
Jun 3, 2017·Leukemia & Lymphoma·Juan Eduardo Megías-VericatSalvador F Aliño
Jan 30, 2007·Clinical Pharmacology and Therapeutics·L W Chinn, D L Kroetz
Aug 25, 2015·Oncotarget·Mohamed Ali MosratiPeter Söderkvist
Apr 3, 2020·International Journal of Molecular Sciences·Lucia Borszéková PulzováMiroslav Chovanec
Apr 16, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Duangjai PiwkhamJoke Beuten
Apr 28, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carlos Fernández de LarreaJoan Bladé
Sep 8, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hamza MameriMounira Amor-Guéret
Jun 27, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lawson EngGeoffrey Liu
May 6, 2021·Journal of Biochemistry·Saud A GohalMing-Cheh Liu
Jun 11, 2021·Expert Opinion on Drug Metabolism & Toxicology·Katsuhisa KurogiMing-Cheh Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.